Advertisement

Advertisement

Breast Cancer
Symptom Management

Pharmacologic Cardioprotection in Women With Nonmetastatic Breast Cancer Receiving Anthracycline-Based Chemotherapy

In an interim analysis of the Italian phase III SAFE trial reported in JAMA Oncology, Livi et al found that a cardioprotective strategy using ramipril and/or bisoprolol reduced the risk of myocardial dysfunction in women with nonmetastatic breast cancer receiving anthracycline-based chemotherapy....

Breast Cancer
Immunotherapy

Update on U.S. Indication for Atezolizumab in PD-L1–Positive Metastatic Triple-Negative Breast Cancer

Genentech, a member of the Roche Group, announced that it has made the decision to voluntarily withdraw the U.S. accelerated approval for atezolizumab (Tecentriq) in combination with nab-paclitaxel for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast...

Breast Cancer
COVID-19

Study Finds Drop in Breast Cancer Screening Rates in Low-Income Communities During the COVID-19 Pandemic

A new study found that during the COVID-19 pandemic, breast cancer screening rates declined among women aged 50 to 74 years at 32 community health centers that serve lower-income populations in the United States. The report, published by Stacey A. Fedewa, PhD, and colleagues in the journal Cancer,...

Breast Cancer

Does Radiotherapy Reduce the Long-Term Risk of Ipsilateral Breast Recurrence in Women With DCIS Who Underwent Lumpectomy?

In an analysis of long-term outcomes from the phase III NRG/RTOG 9804 trial reported in the Journal of Clinical Oncology, Beryl McCormick, MD, and colleagues found that whole-breast irradiation vs observation was associated with reduced risk of all and invasive ipsilateral breast recurrence at 15...

Breast Cancer

I’m a Two-Time Breast Cancer Survivor, and the Experience Has Been Life-Altering

Even before my breast cancer diagnosis in early 2002, the year was shaping up to be life-altering for me and my family. We had moved from Seattle to Houston for a new career opportunity for my husband and were just settling into our new home when I felt a pea-sized nodule in my left breast during a ...

Breast Cancer
Immunotherapy

Sacituzumab Govitecan-hziy for Locally Advanced or Metastatic Triple-Negative Breast Cancer

On April 7, 2021, sacituzumab govitecan-hziy was granted regular approval for treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.1 Sacituzumab...

Breast Cancer

New Guideline Provides Clarity on Timing, Treatment of Axilla in Early-Stage Breast Cancer

ASCO and Ontario Health (Cancer Care Ontario) have collaborated to release a new clinical practice guideline on the management of the axilla in early-stage breast cancer.1 “A lot has changed in the past several years with regard to de-escalating the amount of treatment women are offered in the...

Global Cancer Care
Breast Cancer

Historic, Present, and Future Perspectives on Breast Cancer in Egypt

Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...

Breast Cancer

Extended Follow-up of PALOMA-3 Supports Survival Benefit of Palbociclib Plus Fulvestrant in Advanced Breast Cancer

An updated analysis of the PALOMA-3 randomized, placebo-controlled trial demonstrated continued superiority for the combination of palbociclib (CDK4/6 inhibitor) plus fulvestrant over fulvestrant plus placebo in women with hormone receptor–positive, HER2-negative advanced breast cancer whose...

Breast Cancer

Caution With Robotically Assisted Surgical Devices for Mastectomy: FDA Safety Communication

The U.S. Food and Drug Administration (FDA) is reminding patients and health-care providers that the safety and effectiveness of robotically assisted surgical devices for use in mastectomy procedures or in the prevention or treatment of breast cancer have not been established. In addition, the FDA...

Breast Cancer

Physical Activity and Cognitive Function Before, During, and After Chemotherapy for Breast Cancer

In a study reported in the Journal of Clinical Oncology, Elizabeth A. Salerno, PhD, MPH, and colleagues found that higher levels of physical activity before and during chemotherapy in women with early-stage breast cancer was associated with better cognitive function outcomes at up to 6 months...

Breast Cancer

Prediction Models May Reduce False-Positives in Women With Dense Breasts Undergoing MRI Screening

Prediction models based on clinical characteristics and imaging findings may help reduce the false-positive rate in women with dense breasts who undergo supplemental breast cancer screening with magnetic resonance imaging (MRI), according to a study published by den Dekker et al in the journal...

Breast Cancer
Immunotherapy

Study Identifies Potential Mechanisms of Resistance to Sacituzumab Govitecan-hziy in Patients With Triple-Negative Breast Cancer

Researchers have determined how a highly aggressive type of breast cancer may evade treatment with the compound sacituzumab govitecan-hziy, according to findings published by Coates et al in Cancer Discovery. Their results could help improve therapy and ultimately prolong survival for patients with ...

Breast Cancer
Genomics/Genetics

Simulation Model–Based Clinical Decision Tool for Predicting Benefit of Adjuvant Chemoendocrine vs Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer

As reported in the Journal of Clinical Oncology, Jayasekera et al have developed a clinical decision tool called BTxChoice that can be used with or without the 21-gene recurrence score to estimate the potential benefit of adjuvant chemoendocrine vs endocrine therapy in women with node-negative,...

Breast Cancer

Addition of Entinostat to Exemestane in Aromatase Inhibitor–Resistant, HR-Positive, HER2-Negative Advanced Breast Cancer

As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MB, BCh, MD, and colleagues, the phase III ECOG-ACRIN Cancer Research Group E2112 trial showed no significant improvement in progression-free or overall survival with the addition of the histone deacetylase inhibitor entinostat...

Breast Cancer
Immunotherapy

Meta-analysis of Outcomes With the Addition of Adjuvant Trastuzumab to Chemotherapy for HER2-Positive Breast Cancer

In a study conducted by the Early Breast Cancer Trialists’ Collaborative Group and reported in The Lancet Oncology by Bradley et al, an individual patient data meta-analysis of randomized trials has shown that the addition of adjuvant trastuzumab to chemotherapy reduces the risk of disease...

Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Health-Care Policy
Legislation

Evaluation of Baseline Cancer Mortality Risk in Medicaid Expansion and Nonexpansion States

In a study of National Cancer Database data reported in a research letter in JAMA Oncology, Salazar et al found little difference in baseline cancer mortality rates between U.S. states that expanded Medicaid enrollment and nonexpansion states prior to expansion in 2009 and immediately following...

Breast Cancer
Genomics/Genetics

Outcomes and Behaviors Among Women Receiving or Declining Their Breast Cancer Polygenic Risk Score

A recent study examined patient-reported outcomes and risk-management behaviors of women choosing to receive or decline their breast cancer polygenic risk scores (PRS). The findings were published by Tatiane Yanes, PhD, and colleagues in Genetics in Medicine. The research aimed to look at how the...

Breast Cancer
Immunotherapy

Expert Point of View: Melinda L. Telli, MD

The invited discussant of GeparNuevo,1 Melinda L. Telli, MD, Associate Professor of Medicine at Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, welcomed the additional data...

Breast Cancer
Immunotherapy

Neoadjuvant Durvalumab Improves Long-Term Outcomes in the GeparNuevo Trial

In the phase II GeparNuevo trial, patients with early triple-negative breast cancer receiving the PD-L1 inhibitor durvalumab in addition to chemotherapy as neoadjuvant therapy saw improvements in long-term outcomes. The results were presented at the 2021 ASCO Annual Meeting by Sibylle Loibl, MD,...

Breast Cancer
Immunotherapy

A New Era of Hope for Patients With Triple-Negative Breast Cancer

Triple-negative breast cancer is a particularly devastating subtype of breast cancer, as it is often diagnosed in young women and is associated with an exceptionally poor prognosis. The “triple-negative” designation indicates that the three key features driving most breast cancers (estrogen...

Breast Cancer

Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer

In a phase III trial reported in The New England Journal of Medicine, Michael Gnant, MD, and colleagues found no difference in disease-free survival with 2 vs 5 years of treatment with the aromatase inhibitor anastrozole in postmenopausal women with early hormone receptor (HR)-positive breast...

Breast Cancer

Use of Statins and Survival Outcomes Among Patients With Triple-Negative Breast Cancer

A study published by Nowakowska et al in the journal Cancer has found a significant association between the use of cholesterol-lowering statins and survival rates of patients with triple-negative breast cancer. Since statins are relatively inexpensive, easy to access, and produce minimal side...

Breast Cancer
Issues in Oncology

Racial/Ethnic Disparities in Emergency Department Visits After Breast Cancer Surgery

Among women undergoing surgery for breast cancer, up to 13% will have a postoperative visit to an emergency department, according to recent research. A new study published by Falcone et al in Breast Cancer Research and Treatment discovered there is a greater likelihood that Hispanic and...

Breast Cancer

KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer

The latest analysis of the pivotal phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer.1 This is the first large, randomized, phase III...

Breast Cancer
COVID-19

Incidence of Axillary Adenopathy in Screening or Diagnostic Mammography After COVID-19 Vaccination

In a single-center retrospective study reported in a research letter in JAMA Oncology, Robinson et al found a vaccine-related axillary adenopathy incidence rate of 3% among women undergoing screening or diagnostic mammography within 90 days of receipt of at least one dose of a COVID-19 vaccine....

Breast Cancer
Geriatric Oncology
Genomics/Genetics

Risk of Breast Cancer in Women Older Than Age 65 With Germline Pathogenic Variants in Predisposition Genes

In a study reported in the Journal of Clinical Oncology, Boddicker et al found that women older than age 65 in the general population who carry germline pathogenic variants in established high-risk breast cancer predisposition genes remain at significant risk of late-onset breast cancer and should...

Breast Cancer

Single-Agent Talazoparib Shows Activity in the Neoadjuvant Treatment of Triple-Negative Breast Cancer

For the neoadjuvant treatment of triple-negative breast cancer, the oral poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib yielded promising pathologic complete response rates in the phase II single-arm NEOTALA trial presented at the 2021 ASCO Annual Meeting.1 Preoperative chemotherapy is...

Breast Cancer

Study Explores Rates of Reconstruction for Women With Inflammatory Breast Cancer Undergoing Mastectomy

The percentage of patients with inflammatory breast cancer who select reconstructive surgery after mastectomy—whether immediate or delayed—remains low in spite of improvements in treatment and long-term survival, but the numbers are increasing, according to recent research published by Karadsheh et ...

Breast Cancer

Expert Point of View: Evandro de Azambuja, MD, PhD

“KAITLIN didnot meet its primary endpoint, either in the intent-to-treat or node-positive population,1 but in context with the APHINITY trial [1 year of adjuvant pertuzumab/trastuzumab plus chemotherapy],2 whose outcomes were similar at 3 years, you can appreciate that both arms did extremely...

Breast Cancer

KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy for HER2-Positive Early Breast Cancer

In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease–free survival in the node-positive or intent-to-treat population of women with high-risk, HER2-positive early breast...

Breast Cancer
Immunotherapy

FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage Triple-Negative Breast Cancer

On July 26, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. The FDA also...

breast cancer

HR-Positive/HER2-Positive Metastatic Breast Cancer

In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss the current treatment landscape for hormone receptor (HR)-positive, HER-positive metastatic breast cancer. Dr. Hurvitz presents the case of a 34-year-old woman with de novo metastatic estrogen receptor/progesterone receptor–positive, HER2-positive breast cancer that has metastasized to the liver, bones, and lungs. The faculty discuss the optimal first-line treatment strategy for this patient and review the data surrounding the use of different dual HER2-directed therapies.

breast cancer

ER-Positive/HER2-Positive Breast Cancer and Residual Disease

In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney turn their discussion to treatment options for HER2-positive breast cancer. Dr. Hurvitz presents a case of a 62-year-old woman diagnosed with high-grade cT1N1 estrogen receptor (ER)-positive/progesterone receptor–negative, HER2-positive breast cancer. The faculty discuss whether anthracycline-based regimens should still be utilized in the neoadjuvant setting and the role of T-DM1 as adjuvant therapy for residual disease.

breast cancer

HR-Positive/HER2-Negative Early Breast Cancer

In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss the management of hormone receptor (HR)-positive, HER2-negative early breast cancer. The faculty present the case of a 54-year-old perimenopausal Black woman who has been diagnosed with high-grade T3N1 left breast cancer that is estrogen receptor–positive, progesterone receptor–negative, and HER2-negative. They discuss the utility of genomic assays in helping guide selection of endocrine therapy vs chemotherapy, as well as the use of adjuvant CDK4/6 inhibitors such as palbociclib, abemaciclib, and ribociclib.

breast cancer

Newly Diagnosed HER2-Negative Metastatic Breast Cancer

In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss current treatment options for newly diagnosed HER2-negative metastatic breast cancer. Dr. Hurvitz presents the case of a 49-year-old perimenopausal Latina woman with intermediate-grade T2N1 left breast cancer that is estrogen receptor/progesterone receptor–positive and HER2-negative, with bone and liver metastases. The faculty walk through how they would choose between chemotherapy and endocrine-based options for this patient and discuss recent data on CDK4/6 inhibitors showing improved outcomes in the first-line setting.

Breast Cancer

Breast Cancer in 2030: Predictions From a Breast Cancer Luminary

According to George W. Sledge, Jr, MD, FASCO, Professor of Medicine in the Division of Oncology at Stanford University Medical Center, by the beginning of the next decade, clinicians will be aided by the use of artificial intelligence (AI) in many facets of care and by the approval of a wave of new ...

Breast Cancer

MINDACT Trial Shows ‘Excellent’ Outcomes in Ultra-Low–Risk Breast Cancer

Patients with ultra-low–risk breast cancer, as classified by the MammaPrint 70-gene assay, had “excellent” long-term outcomes regardless of clinical risk or receipt of adjuvant therapy, a new analysis of the MINDACT trial has shown.1 In a separate study, a retrospective analysis of the National...

Breast Cancer

I’m Alive by Sheer Force of Will—and a Lot of Luck

From the moment I felt a searing pain go through my right breast, I had a premonition that something was very wrong. Although I couldn’t feel anything unusual when I did a breast self-exam, I made an appointment with my gynecologist for a more thorough clinical breast exam and a mammogram. Because...

Breast Cancer

Factoring Fertility Preservation Into Breast Cancer Treatment

Breast cancer is the most commonly diagnosed cancer in women of reproductive age. Approximately 10% of breast cancers are diagnosed in this age group.1 Young age at diagnosis is an adverse prognostic factor, and most young women will be offered chemotherapy and/or endocrine therapy, both of which ...

Breast Cancer
Myelodysplastic Syndromes

FDA Pipeline: Designations for Therapies in Myelodysplastic Syndromes and Triple-Negative Breast Cancer

Recently, the U.S. Food and Drug Administration (FDA) granted special designation status to treatments for myelodysplastic syndromes and advanced triple-negative breast cancer. Breakthrough Therapy Designation for Venetoclax in Combination With Azacitidine for  Myelodysplastic Syndromes Venetoclax...

Breast Cancer

Outcomes in Patients With HER2-Low–Positive Breast Cancer Participating in Neoadjuvant Clinical Trials

In a pooled analysis of individual patient data from breast cancer neoadjuvant clinical trials reported in The Lancet Oncology, Carsten Denkert, MD, and colleagues found that pathologic complete response and survival rates for patients with HER2-low–positive vs HER2-zero tumors differed according...

Breast Cancer

Is There a Disease-Free Survival Benefit With Adjuvant Celecoxib in HER2-Negative Breast Cancer?

In the phase III REACT trial reported in JAMA Oncology, R. Charles Coombes, MD, PhD, and colleagues found no disease-free survival benefit with the addition of 2 years of adjuvant celecoxib vs placebo to conventional adjuvant treatment in patients with HER2-negative breast cancer. Study Details...

Breast Cancer
Immunotherapy

Efficacy of Dendritic Cell Vaccines Plus Standard Therapy for Breast Cancer

A report published by Oba et al in the Journal for ImmunoTherapy of Cancer shares new data on combining standard treatment for breast cancer with a particular form of cancer immunotherapy—dendritic cell vaccines. The study is reportedly the first to demonstrate that in situ dendritic cell vaccines...

Breast Cancer

Breast-Conserving Surgery Plus Radiotherapy May Yield Better Survival Than Mastectomy With or Without Radiotherapy

In a Swedish cohort study reported in JAMA Surgery, de Boniface et al found that breast-conserving surgery plus radiation therapy for women with breast cancer was associated with better survival vs mastectomy with or without radiotherapy in analysis adjusting for comorbidities and socioeconomic...

Breast Cancer
Cost of Care

Study Estimates Costs Associated With Metastatic Breast Cancer Treatment May Increase Substantially in the Coming Decade

A study from the UNC Center for Health Promotion and Disease Prevention (HPDP) estimates that annual costs associated with metastatic breast cancer treatment among women in the United States will total $152.4 billion in 2030—nearly two and a half times the estimate for 2015 costs—due to an increase ...

Breast Cancer
Survivorship

Pregnancy Outcomes and Maternal Complications Among Survivors of Breast Cancer

In a systematic review and meta-analysis reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, PhD, and colleagues found that breast cancer survivors were less likely to have subsequent pregnancy vs the general population and more likely to have preterm birth. However, no reduction...

Breast Cancer
COVID-19

Initial Pandemic-Related Disruptions in Breast Cancer Care May Result in Increased Mortality Over the Next Decade

During the early months of the COVID-19 pandemic in 2020, elective medical procedures, including screenings for breast cancer, were curtailed to prioritize urgent medical needs and reduce the risk of spreading the coronavirus in health-care settings. A study showed that, as of May 2020, preventive...

Breast Cancer
Immunotherapy

Real-World Survival Outcomes With Pertuzumab Plus T-DM1 for HER2-Positive Metastatic Breast Cancer

In a Canadian population-based retrospective cohort study reported in JAMA Oncology, Ethier et al identified real-world survival outcomes among women receiving pertuzumab and trastuzumab emtansine (T-DM1) for stage IV HER2-positive breast cancer, observing that outcomes appeared to be poorer than...

breast cancer

Terry P. Mamounas, MD, MPH, on Breast Cancer: Extended Aromatase Inhibitor Therapy

Terry P. Mamounas, MD, MPH, of the University of Florida Health Cancer Center, discusses results from the NRG Oncology/NSABP B-42 study, which examined the Breast Cancer Index and its ability to predict whether extended treatment with letrozole benefits patients with hormone receptor–positive breast cancer (Abstract 501).

Advertisement

Advertisement

Advertisement